Oragenics, Inc.

Latest News

Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

Innovative Biopharmaceuticals from Oral Science

Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease.

Learn More About Oragenics

Oragenics Acquires Noachis Terra, Inc.

NIH-created SARS-CoV-2 (COVID-19) Spike Protein Vaccine Technology could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”).

Learn More about Noachis Terra

Learn More about the Acquisition of Noachis Terra

Fighting Global Bacterial Antibiotic Resistance

Oragenics, in collaboration with Precigen, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.

Learn More About Lantibiotics

Sign up for email updates

Be the first to receive breaking news

Sign Up

OG716 for C. difficile Infection

OG716 is a molecule derived from our lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including an animal model for Clostridium difficile infection in enteritis.

More on OG716 »

AG013 for Oral Mucositis

AG013 represents a promising product from a truly innovative platform for the prevention of oral mucositis in cancer patients.

More on AG013 »

Investors Presentation

View our latest Corporate Presentation

View presentation »
Oragenics Pesentation
NYSE American OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Last Updated: